A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Vaxart Biosciences, Inc. was originally incorporated in California under the name West Coast Biologicals, Inc. in March 2004 and changed its name to Vaxart, Inc. (“Private Vaxart”) in July 2007, when it reincorporated in the state of Delaware. On February 13, 2018, Private Vaxart completed a reverse merger (the “Merger”) with Aviragen Therapeutics, Inc. (“Aviragen”), pursuant to which Private Vaxart survived as a wholly owned subsidiary of Aviragen. Under the terms of the Merger, Aviragen changed its name to Vaxart, Inc. and Private Vaxart changed its name to Vaxart Biosciences, Inc. Unless otherwise indicated, all references to “Vaxart,” “we,” “us,” “our” or the “Company” in this Annual Report mean Vaxart, Inc., the combined company. We are a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on our Vector-Adjuvant-Antigen Standardized Technology (“VAAST”) proprietary oral vaccine platform.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 148M | - | - | - | - | - |
| Net Income | -51M | -67M | -82M | -108M | -70M | -32M |
| EPS | $-0.22 | $-0.29 | $-0.36 | $-0.62 | $-0.52 | $-0.36 |
| Free Cash Flow | -30M | -45M | -72M | -104M | -65M | -25M |
| ROIC | -18.5% | -88.9% | -113.9% | -97.4% | -37.6% | -26.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.82 | 0.59 | 0.39 | 0.18 | 0.24 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -49M | -66M | -83M | -115M | -73M | -30M |
| Operating Margin | -33.0% | - | - | - | - | - |
| ROE | -189.5% | -114.7% | -142.7% | -97.4% | -37.6% | -26.1% |
| Shares Outstanding | 240M | 228M | 228M | 174M | 136M | 90M |
Vaxart, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Vaxart, Inc. (VXRT) has a 5-year average return on invested capital (ROIC) of -72.8%. This is below average and may indicate limited pricing power.
Vaxart, Inc. (VXRT) has a market capitalization of $168M. It is classified as a small-cap stock.
Vaxart, Inc. (VXRT) does not currently pay a regular dividend.
Vaxart, Inc. (VXRT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Vaxart, Inc. (VXRT) generated $-45 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Vaxart, Inc. (VXRT) has a debt-to-equity ratio of 1.82. This indicates higher leverage, which may increase financial risk.
Vaxart, Inc. (VXRT) reported earnings per share (EPS) of $-0.29 in its most recent fiscal year.
Vaxart, Inc. (VXRT) has a return on equity (ROE) of -114.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for Vaxart, Inc. (VXRT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Vaxart, Inc. (VXRT) has a book value per share of $0.26, based on its most recent annual SEC filing.